Novavax Inc. closed 61.59% short of its 52-week high of $17.81, which the company achieved on July 26th.

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to ...

Key Points Canopy Growth seems unable to overcome the industrywide challenges it faces.Novavax's recent quarterly update, though strong, says little about its prospects. 10 stocks we like better than ...

Health's first quarter saw notable gains, with management attributing performance to strong Medicare Advantage enrollment ...